MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma
Zaman S, Chobrutskiy BI, Sikaria D, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival for low-grade glioma. Oncology Reports 2018, 41: 1359-1366. PMID: 30535461, DOI: 10.3892/or.2018.6896.Peer-Reviewed Original ResearchMAPT expressionSurvival rateΑ-synuclein gene expressionDisease-free survivalCentral nervous systemLow-grade gliomasAssociation of MAPTRate of survivalCancer Genome AtlasBreast cancerNeurodegenerative roleTau expressionBrain cancerNervous systemNeurological disordersTau proteinMAPT geneHigh expressionCancerGenome AtlasPrecursor proteinExpression levelsSuch associationsSurvivalTauRecovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade
Chobrutskiy BI, Zaman S, Tong WL, Diviney A, Blanck G. Recovery of T-cell receptor V(D)J recombination reads from lower grade glioma exome files correlates with reduced survival and advanced cancer grade. Journal Of Neuro-Oncology 2018, 140: 697-704. PMID: 30382482, DOI: 10.1007/s11060-018-03001-1.Peer-Reviewed Original ResearchConceptsLow-grade gliomasT cell receptorCancer gradeImmune systemExome filesT-cell biomarkersDisease-free survivalT lymphocyte infiltrationPrimary tumor siteLGG survivalLymphocyte infiltrationCancer survivalPrimary tumorPancreatic cancerDisease progressionUseful biomarkerB cellsGrade gliomasSurvival rateTumor siteReduced survivalSurvivalSuch associationsBiomarkersReceptorsImmune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates
Tong WL, Callahan BM, Tu YN, Zaman S, Chobrutskiy BI, Blanck G. Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates. Breast Cancer Research And Treatment 2018, 173: 167-177. PMID: 30229447, DOI: 10.1007/s10549-018-4961-1.Peer-Reviewed Original ResearchConceptsImmune receptor recombinationsSpecific HLA allelesExome filesHLA typesBreast cancerHLA allelesSurvival rateImmune checkpoint inhibitor therapyImproved disease-free survivalDisease-free outcomeCheckpoint inhibitor therapyT cell receptor VUse of immunotherapyDisease-free survivalSegment usageB cell biomarkersBreast cancer subgroupsHLA allele combinationsBetter survival rateBreast cancer samplesBreast tumor samplesGene segment usageSurvival distinctionsInhibitor therapyImmune characterization